DONALDSON/SOLARIS-BIOTEC
Donaldson brand Solaris Biotech, a leading innovator and manufacturer of bioreactors, fermenters and tangential flow filtration systems has entered an agreement with Wildtype, a San Francisco-based company focused on creating cultivated seafood. The two companies will engage in a collaborative development program to design a next generation family of bioreactor systems to help meet the growing demand for seafood.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20221115006265/en/
Solaris Industrial Scale Bioreactor Systems. (Photo: Business Wire)
Food is fundamental to our existence, and food demand is increasing with rising income levels and a multiplying global population. Alternative proteins are experiencing rapid growth as a result of these trends, and cell cultivated proteins are at the forefront of these innovations. “Solaris, with our specialized bioprocessing equipment, is uniquely positioned to play a significant role in the advancement of new cultured food technologies,” said Matteo Brognoli, Managing Director of Solaris. “Alternative proteins have become the fastest growing segment for bioreactor systems and we are proud that our cultivators are the enabling technology for this leap in the food industry.”
“Wildtype is on a mission to produce the cleanest, most delicious seafood on the planet,” said Justin Kolbeck, Wildtype CEO. “Annual global seafood consumption is expected to increase an additional 23 million tons by 2030 and one of the most important pieces in the productive infrastructure are the cultivators used to grow cells. With Solaris’ technologically advanced solutions we have found the right partner to help us scale and make our products more affordable and accessible.”
About Solaris
Solaris, a Donaldson brand, is a leading innovator and manufacturer of fermenters, bioreactors, tangential flow (TFF) and depth (FFF) filtration systems used for a variety of applications in the pharmaceutical, biopharmaceutical and food industries. Its product and development teams create solutions at all scales, from benchtop R&D systems to complete engineered solutions tailored to individual customer needs. Since November 2021, Solaris has been a part of Donaldson Company (NYSE: DCI) and its expansion into life sciences. Discover the full scope of Solaris products and capabilities at solarisbiotech.com.
About Wildtype
Wildtype is on a mission to create the cleanest, most sustainable seafood on the planet, starting with sushi-grade salmon. The company is pioneering cellular agriculture to protect wild species and our oceans, and to reverse trends of global food insecurity. Wildtype will provide consumers with a new option for real seafood that provides the same nutritional benefits as the most pristine wild-caught fish, without common contaminants such as mercury, microplastics, antibiotics or pesticides.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221115006265/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Aesyra Demonstrates Significant Sleep Bruxism Reduction in Clinical Study26.1.2026 09:00:00 CET | Press release
Aesyra SA, a Swiss medtech company developing innovative digital therapeutics for dental and sleep-related disorders, today announced the successful completion of its clinical investigation evaluating the efficacy and safety of AesyBite™ Active, an intelligent oral appliance designed to treat and prevent sleep bruxism through biofeedback. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260126533019/en/ AesyBite Custom smart nightguard by Aesyra SA. The clinical investigation demonstrated that AesyBite™ Active achieved a statistically significant and clinically meaningful reduction in sleep bruxism activity, exceeding the predefined performance target. Strong and robust clinical outcomes In the study (Identifier: NCT06153810), involving 26 adult patients with confirmed sleep bruxism, activation of the AesyBite Active biofeedback system resulted in a 60.6% reduction in total sleep bruxism duration per hour compared to baseline
Franklin Templeton Aligns Alternative Credit Firms Under BSP Brand26.1.2026 08:58:00 CET | Press release
Benefit Street Partners and Alcentra align under a single, refreshed BSP brand.Move reflects client demand for a specialist, integrated and global credit platform.Franklin Templeton’s alternative credit platform on track to exceed $100bn in 2026.BSP outlines further growth plans including expansion in the Middle East and Asia.New research says 51% of institutional investors will increase credit allocation in 2026.81% of institutions say a specialist focus on credit is the top attribute for performance. Franklin Templeton’s US and European alternative credit businesses, Benefit Street Partners and Alcentra, have now aligned under an updated Benefit Street Partners (BSP) brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260123270080/en/ David Manlowe, CEO of Benefit Street Partners The move is the final step in BSP and Alcentra’s integration – two pioneering alternative credit firms that Franklin Templeton acquired in 2019
Samsung Epis Holdings Reports Fourth Quarter and Fiscal Year 2025 Financial Results26.1.2026 08:00:00 CET | Press release
In its first financial results announcement after the spin-off, Samsung Bioepis recorded FY2025 revenue of KRW 1.672 trillion, highest annual revenue in its 14-year historyExcluding milestone revenue, annual sales revenue grew 28% year-over-year (YoY), recording KRW 1.626 trillion, with 101% YoY growth in operating profit to KRW 330.8 billion Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced financial results for the fourth quarter and fiscal year 2025. “We are very pleased to report strong year-to-date sales growth in our first financial results following the spin-off. Our organic growth has been driven by solid performance across our biosimilars portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are continuing to make meaningful progress in our regulatory and commercial milestones with our existing biosimilars portfolio, while strategically
Syngenta and Statkraft Sign Five-Year Virtual Power Purchase Agreement26.1.2026 08:00:00 CET | Press release
Virtual wind PPA with guarantees of origin to decarbonize Syngenta's plants in Europe Important element in carbon reduction journey for Syngenta AG Syngenta, one of the world’s biggest agricultural innovation companies, and Statkraft, a leading provider of innovative green energy solutions in Europe, have signed a virtual power purchase agreement (vPPA) covering Syngenta’s CP & Seeds operations for a period of five years. The volume amounts to 125 GWh per year and a total of 625 GWh of green electricity by the end of the contract in 2030. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260125701845/en/ Syngenta and Statkraft sign five-year virtual power purchase agreement With the vPPA, Statkraft is supporting Syngenta in advancing its sustainability strategy through the purchase of renewable energy. "This is Syngenta's first vPPA, marking a pivotal step in our decarbonization strategy," said Rachel Stenson Bugnon, Global Hea
Merz Therapeutics Submits Application to the European Medicines Agency for New Indication of XEOMIN® in Pediatric Spasticity26.1.2026 08:00:00 CET | Press release
Merz Therapeutics, a leading player in neurology-focused specialty pharma, today announced that it has completed the regulatory submission for XEOMIN® (incobotulinumtoxinA) for the treatment of spasticity of the lower and upper limb in children and adolescents aged 2–17 years in the European Union (EU) and European Economic Area (EEA). If approved, the indication would expand access to an established botulinum neurotoxin therapy for some of the youngest and most vulnerable patients across Europe. Spasticity is a common and often debilitating condition in children and adolescents with certain neurological conditions, leading to increased muscle tone that can significantly limit movement, function and independence. One of the most common underlying causes of spasticity in children is cerebral palsy (CP), the most frequent motor disability in childhood, with spastic forms accounting for approximately 80% of all cases. In more severe cases, spasticity associated with CP can also affect spe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom